Lineage Cell Therapeutics (LCTX) Short term Debt (2014 - 2021)
Lineage Cell Therapeutics' (LCTX) quarterly Short term Debt came in at $523000.0 in Q1 2021, little changed quarter-over-quarter from $523000.0 in Q4 2020.
Lineage Cell Therapeutics (LCTX) Short term Debt (2014 - 2021) Analysis & Trends
Lineage Cell Therapeutics' Short term Debt history runs 4 years deep, the most recent figure standing at $523000.0 for Q1 2021.
- On a quarterly basis, Short term Debt changed N/A year-over-year to $523000.0 in Q1 2021; TTM through Mar 2021 was $523000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $523000.0, changed N/A from the prior year.
- Short term Debt steadied at $523000.0 in Q1 2021 per LCTX's latest filing, from $523000.0 in the prior quarter.
- Across five years, Short term Debt topped out at $523000.0 in Q2 2020 and bottomed at $523000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 523,000.00 |
| Dec 31, 2020 | 523,000.00 |
| Sep 30, 2020 | 523,000.00 |
| Jun 30, 2020 | 523,000.00 |
| Dec 31, 2015 | 26,000.00 |
| Jun 30, 2015 | 3,000.00 |
| Mar 31, 2015 | 17,307.00 |
| Dec 31, 2014 | 31,000.00 |
| Sep 30, 2014 | 44,963.00 |
| Jun 30, 2014 | 57,500.00 |